Costimulatory signaling pathway

The "Costimulatory signaling pathway" is not a single molecular target but rather refers to a network of secondary signals required for full activation of lymphocytes—primarily T cells—during an immune response. These pathways involve interactions between costimulatory receptors on lymphocytes (such as CD28, ICOS, 4‑1BB/CD137) and their ligands on antigen-presenting cells or other immune cells. The primary function is to provide essential signals that complement antigen recognition via the T cell receptor; without these signals, lymphocytes may become anergic or undergo apoptosis instead of activating robustly. Key molecules in this network include members of the immunoglobulin superfamily (CD28 family) and TNF receptor superfamily. These pathways regulate critical processes such as cytokine secretion, proliferation, differentiation into effector subtypes or regulatory phenotypes, and maintenance of tolerance versus immunity. Dysregulation can contribute to diseases like cancer (where enhancing co-stimulation may boost anti-tumor immunity) or autoimmunity/inflammation (where blocking co-stimulation can dampen pathological responses)[1][2][3][5]. Therapeutic interventions do not target "the costimulatory signaling pathway" as a whole but rather focus on specific receptors/ligands within it—for example with monoclonal antibodies against CTLA‑4 or agonists for OX40/4‑1BB in cancer immunotherapy. Because "Costimulatory signaling pathway" is not itself a discrete protein/gene/molecule but rather describes a class of biological processes involving many different targets with distinct properties and druggability profiles—it should not be considered a canonical therapeutic target entity suitable for structured annotation at the level requested here[1][2].

Other names

Co-stimulation pathwayT cell costimulatory pathwayCostimulatory signal transductionCostimulatory molecule signaling